Archive · 25 Sep 2025
Piramal Pharma: Initiated with 'Add' Rating, ₹276 Target
Imagine a company called Piramal Pharma, which is like a builder in the healthcare world.
A financial analyst has looked closely at this builder's different projects: CDMO, CHG and PCH.
The analyst thinks the company is doing well and has given it an "Add" rating, meaning they think the company's stock is worth buying.
They set a target price of ₹276 per share.
The analyst looked at the company's different businesses: making medicines and health products and how much money they make.
Although some risks exist, such as timing with biotech funding and regulatory outcomes, the analyst believes Piramal Pharma is a good investment.
Broker initiated coverage on Piramal Pharma with an 'Add' rating.
The target price for Piramal Pharma is set at ₹276.
Piramal Pharma's CDMO arm focuses on research, development, and manufacturing.
The company has a complex hospital generics segment.
The PCH segment offers steady cash generation through brands and distribution.
- Who
- Piramal Pharma
- What
- Brokerage initiated coverage with an 'Add' rating and a target price of ₹276.
- When
- Published on September 25, 2025
- Where
- N/A
- Why
- Based on deep-dive analysis, peer comparison, and key modalities, considering CDMO, CHG and PCH segments.
- Company
- Piramal Pharma
- Rating
- Add
- Target Price
- ₹276
- CMP
- ₹195.20
- FY27F EBITDA
- ₹1,749 crore
- Net Debt
- ₹4,625 crore
- Valuation Method
- 24.6x EV/EBITDA multiple
- Published Date
- September 25, 2025